Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Curtin University | OTHER |
| University of Melbourne | OTHER |
| Arba Minch University | OTHER |
| Papua New Guinea Institute of Medical Research |
Not provided
Not provided
Not provided
Not provided
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (<30% activity)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with G6PD intermediate status receive another active regimen appropriate for intermedia | Active Comparator | G6PD activity 30-<70% |
|
| Participants withG6PD deficient status receive a specific treatment regimen appropriate for deficie | Active Comparator | G6PD activity ≤30% |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days | Drug | Primaquine 1mg/kg/day for 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Safety and efficacy of high dose primaquine |
| 6 Months |
Not provided
Not provided
Inclusion Criteria:
• P. vivax peripheral parasitaemia (mono-infection)
Exclusion Criteria:
• Danger signs or symptoms of severe malaria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr Marcus Lacerda | Recruiting | Manaus | Brazil |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| OTHER_GOV |
| Mahidol Oxford Tropical Medicine Research Unit | OTHER |
| Oxford University Clinical Research Unit, Vietnam | OTHER |
| Indonesia University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
| Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose). | Drug | 8 weekly Primaquine (0.75mg/kg dose). |
|
| Arba Minch General Hospital | Not yet recruiting | Arba Minch | Ethiopia |
|
| Dr Moses Laman and Dr Brioni Moore | Recruiting | Alexishafen | Madang Province | Papua New Guinea |
|
| Papua New Guinea Institute of Medical Research | Recruiting | Port Moresby | Magang | Papua New Guinea |
|
| ID | Term |
|---|---|
| D016780 | Malaria, Vivax |
| D005955 | Glucosephosphate Dehydrogenase Deficiency |
| ID | Term |
|---|---|
| D008288 | Malaria |
| D011528 | Protozoan Infections |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
| D000096724 | Mosquito-Borne Diseases |
| D000079426 | Vector Borne Diseases |
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011319 | Primaquine |
| ID | Term |
|---|---|
| D000634 | Aminoquinolines |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided